Can lung cancer be prevented using a drug?
Researchers have identified blood proteins that may predict lung cancer years in advance, leading to speculation about using the drug Canakinumab for prevention. However, experts warn that medical research is complex and that the drug's efficacy for cancer prevention remains unproven despite its success in cardiovascular trials.
Why it matters
It highlights the danger of oversimplifying complex medical research into 'miracle cure' headlines, which can lead to public misunderstanding of clinical trial data.
On June 4 2026, a paper was published in the journal Cell , in which researchers from The Francis Crick Institute, University College London and elsewhere, identified a set of blood proteins that appeared to predict lung cancer five years before it became clinically apparent. In addition, the researchers proposed that a human monoclonal antibody called Canakinumab, which targets interleukin-1 beta (a component of the body’s immune response), might reduce the risk of lung cancer among individuals with this protein signature, based on a retrospective analysis of an earlier clinical trial.
The article provides a balanced, evidence-based critique of sensationalized medical reporting.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in